Results 101 to 110 of about 182,666 (399)

Idiopathic pulmonary fibrosis - problematic rare lung disease. Pathogenesis, diagnosis, treatment and prognosis

Journal of Education, Health and Sport, 2022
Introduction: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease most often affecting people over the age of 50. Causes and pathogenesis of the disease are not fully understood.
Aleksander Kłos, Justyna Szydłowska, Olga Żuchnik, Olgierd Król, Piotr Kwiatkowski, Beata Kuczyńska, Magdalena Czelej, Konrad Gładysz, Krzysztof Gieroba, Marcin Szydłowski   +9 more
doaj   +1 more source

Evaluation of automated airway morphological quantification for assessing fibrosing lung disease [PDF]

arXiv, 2021
Abnormal airway dilatation, termed traction bronchiectasis, is a typical feature of idiopathic pulmonary fibrosis (IPF). Volumetric computed tomography (CT) imaging captures the loss of normal airway tapering in IPF. We postulated that automated quantification of airway abnormalities could provide estimates of IPF disease extent and severity.
arxiv  

Management of Idiopathic Pulmonary Fibrosis [PDF]

Annals of Pharmacotherapy, 2019
Objective: Provide information for pharmacists on idiopathic pulmonary fibrosis (IPF) and its treatment. Study Selection and Data Extraction: All articles with data from randomized controlled trials of nintedanib or pirfenidone were reviewed. Data Synthesis: IPF is a progressive and ultimately fatal interstitial lung disease characterized by decline ...
Roy A. Pleasants, Roy A. Pleasants, Robert M. Tighe   +2 more
openaire   +3 more sources

Gasotransmitters in Modern Medicine: Promises and Challenges in the Use of Porous Crystalline Carriers

Advanced Healthcare Materials, EarlyView.
This perspective provides an overview of the growing interest in utilizing various gasotransmitters—small gaseous signaling molecules namely nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H2S)—for several therapeutic applications, with emphasis on the potential use of porous materials as carriers to provide safe and controlled local ...
Rosana V. Pinto, Moisés L. Pinto, Christian Serre   +2 more
wiley   +1 more source

Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor‐induced interstitial lung disease in patients with non‐small cell lung cancer

Thoracic Cancer, Volume 14, Issue 1, Page 73-80, January 2023., 2023
We retrospectively investigated the clinical significance of Interstitial lung abnormalities (ILAs) in patients with NSCLC receiving immune checkpoint inhibitor (ICI). The incidence of early‐onset ICI‐ related interstitial lung disease (ICI‐ILD) was significantly higher in patients with than in patients without nonfibrotic ILAs.
Daiki Murata, Koichi Azuma, Goushi Matama, Yoshiaki Zaizen, Norikazu Matsuo, Kenta Murotani, Takaaki Tokito, Tomoaki Hoshino   +7 more
wiley   +1 more source

TGF-beta 1 induces human alveolar epithelial to mesenchymal cell transition (EMT) [PDF]

, 2005
Background: Fibroblastic foci are characteristic features in lung parenchyma of patients with idiopathic pulmonary fibrosis (IPF). They comprise aggregates of mesenchymal cells which underlie sites of unresolved epithelial injury and are associated with ...
A Atfi, A Desmouliere, A Desmouliere, CM Ewing, D Upadhyay, DA Vesey, DG. Hoyt, DW Powell, DW Powell, DY Rhyu, E Healy, E Piek, EE Moussad, EP Bottinger, F Strutz, G Raghu, GR Grotendorst, HW Yao, J Fan, J Gauldie, J Nightingale, J Yang, JT Allen, JT Allen, K Vleminckx, KA Foster, LH Pan, M Kelly, M Selman, M Selman, M Whitman, N Khalil, N Khalil, N Khalil, NA Bhowmick, NA Wahab, NA Wahab, NA Wahab, P Bonniaud, P Sharmila, PJ Miettinen, PJ Sime, R Derynck, R Kalluri, S Hashimoto, T Maeyama, TE King Jr, TJ Gross, V Mermall, Y Higashimoto, Y Liu   +50 more
core   +4 more sources

Translational pharmacology of an inhaled small molecule αvβ6 integrin inhibitor for idiopathic pulmonary fibrosis

Nature Communications, 2020
The αvβ6 integrin plays a key role in the activation of transforming growth factor-β (TGFβ), a pro-fibrotic mediator that is pivotal to the development of idiopathic pulmonary fibrosis (IPF).
Alison E. John, R. Graves, K. Pun, G. Vitulli, E. Forty, P. Mercer, Josie Morrell, John W. Barrett, Rebecca F. Rogers, Maryam Hafeji, L. Bibby, E. Gower, Valerie S. Morrison, Yim Man, James A Roper, Jeni C. Luckett, L. Borthwick, Ben S. Barksby, R. Burgoyne, Rory Barnes, Joelle Le, David J. Flint, S. Pyne, A. Habgood, Louise A. Organ, Chitra Joseph, Rochelle C. Edwards-Pritchard, Toby M. Maher, Andrew J. Fisher, N. S. Gudmann, D. J. Leeming, Rachel C. Chambers, P. Lukey, Richard P. Marshall, Simon J.F. Macdonald, R. Jenkins, Robert J Slack   +36 more
semanticscholar   +1 more source

Inhalable Hsa‐miR‐30a‐3p Liposomes Attenuate Pulmonary Fibrosis

Advanced Science, EarlyView.
The study explores inhalable hsa‐miR‐30a‐3p‐loaded liposomes as a treatment for bleomycin‐induced pulmonary fibrosis in mice. Hsa‐miR‐30a‐3p is electroporated into liposomes and formulated into a dry powder for inhalation. Delivered via dry powder inhalation, it improves pulmonary function, promotes myofibroblast de‐differentiation by targeting CNPY2 ...
Shuo Liu, Kristen D. Popowski, Christina M. Eckhardt, Weihang Zhang, Junlang Li, Yujia Jing, Dylan Silkstone, Elizabeth Belcher, Megan Cislo, Shiqi Hu, Halle Lutz, Asma Ghodsi, Mengrui Liu, Phuong‐Uyen C. Dinh, Ke Cheng   +14 more
wiley   +1 more source

A feasibility, randomised controlled trial of a complex breathlessness intervention in idiopathic pulmonary fibrosis (BREEZE-IPF): study protocol [PDF]

, 2019
Introduction Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease that causes breathlessness and cough that worsen over time, limiting daily activities and negatively impacting quality of life.
Allgar, V., Cohen, J. F., Crooks, M. G., Dyson, J., English, A., Hargreaves, I., Hart, S., Hussain, J., Johnson, M., Richardson, G., Swan, F., Twiddy, M., Wright, C.   +12 more
core   +3 more sources

Lactylation‐Driven HECTD2 Limits the Response of Hepatocellular Carcinoma to Lenvatinib

Advanced Science, EarlyView.
HECTD2 serves as an E3 ubiquitin ligase of KEAP1 to facilitate the antioxidative response and contributes to lenvatinib resistance in hepatocellular carcinoma. Lactylation of histone 3 on lysine residue 18 drives HECTD2 transcription. Targeting HECTD2 using PLGA‐PEG‐based nanoparticles offers novel strategies to overcome lenvatinib resistance in ...
Runyu Dong, Yao Fei, Yiren He, Peng Gao, Bo Zhang, Menglin Zhu, Zhixiong Wang, Longfei Wu, Shuai Wu, Xiaoming Wang, Juan Cai, Zhiqiang Chen, Xueliang Zuo   +12 more
wiley   +1 more source